These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 16620147)

  • 61. Evolving treatment strategies for chronic refractory angina.
    Yang EH; Barsness GW
    Expert Opin Pharmacother; 2006 Feb; 7(3):259-66. PubMed ID: 16448320
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Measuring antianginal drug efficacy using exercise testing for chronic angina: improved exercise performance with ranolazine, a pFOX inhibitor.
    Chaitman BR
    Curr Probl Cardiol; 2002 Dec; 27(12):527-55. PubMed ID: 12501118
    [No Abstract]   [Full Text] [Related]  

  • 63. Safety and efficacy of extended-release ranolazine in patients aged 70 years or older with chronic stable angina pectoris.
    Rich MW; Crager M; McKay CR
    Am J Geriatr Cardiol; 2007; 16(4):216-21. PubMed ID: 17617747
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Long-Term (3 Years) Outcomes of Ranolazine Therapy for Refractory Angina Pectoris (from the Ranolazine Refractory Registry).
    Storey KM; Wang J; Garberich RF; Bennett NM; Traverse JH; Arndt TL; Schmidt CW; Henry TD
    Am J Cardiol; 2020 Aug; 129():1-4. PubMed ID: 32540170
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure.
    Rupp H; Zarain-Herzberg A; Maisch B
    Herz; 2002 Nov; 27(7):621-36. PubMed ID: 12439634
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Anti-ischemic and pleiotropic effects of ranolazine in chronic coronary syndromes.
    Manolis A; Kallistratos M; Poulimenos L; Thomopoulos C
    Am J Med Sci; 2024 Mar; 367(3):155-159. PubMed ID: 38072070
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The evolving role of medical therapy for chronic stable angina.
    Eid F; Boden WE
    Curr Cardiol Rep; 2008 Jul; 10(4):263-71. PubMed ID: 18611360
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Ranolazine (ranexa) for chronic angina.
    Med Lett Drugs Ther; 2006 Jun; 48(1236):46-7. PubMed ID: 16770296
    [No Abstract]   [Full Text] [Related]  

  • 69. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes.
    Timmis AD; Chaitman BR; Crager M
    Eur Heart J; 2006 Jan; 27(1):42-8. PubMed ID: 16176940
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Ranolazine: an anti-anginal drug with further therapeutic potential.
    Reffelmann T; Kloner RA
    Expert Rev Cardiovasc Ther; 2010 Mar; 8(3):319-29. PubMed ID: 20222810
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The use of ranolazine in cardiovascular disease.
    Schofield RS; Hill JA
    Expert Opin Investig Drugs; 2002 Jan; 11(1):117-23. PubMed ID: 11772326
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions.
    McClellan KJ; Plosker GL
    Drugs; 1999 Jul; 58(1):143-57. PubMed ID: 10439934
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Use of ranolazine in patients with stable angina pectoris.
    Khera S; Kolte D; Aronow WS
    Cardiology; 2014; 128(3):251-8. PubMed ID: 24852049
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Metabolic antianginal agent ranolazine offers good symptom relief in a patient with inoperable severe aortic stenosis.
    Athauda-Arachchi P; Lang C
    Cardiovasc Ther; 2012 Aug; 30(4):e210-1. PubMed ID: 21884008
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Ranolazine (RS-43285): a preliminary study of a new anti-anginal agent with selective effect on ischaemic myocardium.
    Jain D; Dasgupta P; Hughes LO; Lahiri A; Raftery EB
    Eur J Clin Pharmacol; 1990; 38(2):111-4. PubMed ID: 2110906
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Addition of zatebradine, a direct sinus node inhibitor, provides no greater exercise tolerance benefit in patients with angina taking extended-release nifedipine: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. The Zatebradine Study Group.
    Frishman WH; Pepine CJ; Weiss RJ; Baiker WM
    J Am Coll Cardiol; 1995 Aug; 26(2):305-12. PubMed ID: 7608428
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images.
    Venkataraman R; Belardinelli L; Blackburn B; Heo J; Iskandrian AE
    JACC Cardiovasc Imaging; 2009 Nov; 2(11):1301-9. PubMed ID: 19909934
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Ranolazine: a novel therapeutic option in chronic stable angina.
    Jose J; Jimmy B; Saravu K; Shastry BA
    Kathmandu Univ Med J (KUMJ); 2007; 5(4):596-9. PubMed ID: 18604102
    [No Abstract]   [Full Text] [Related]  

  • 79. Ranolazine for the treatment of refractory angina in a veterans population.
    Greene RS; Rangel RM; Edwards KL; Chastain LM; Brouse SD; Alvarez CA; Collins LJ; Brilakis ES; Banerjee S
    Cardiovasc Revasc Med; 2012; 13(2):141.e1-5. PubMed ID: 21856249
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Does ranolazine have a place in the treatment of acute coronary syndromes?
    Newby LK; Peterson ED
    JAMA; 2007 Apr; 297(16):1823-5. PubMed ID: 17456825
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.